Trials / Completed
CompletedNCT01102400
A Study of MEDI-575 in Patients With Advanced Solid Malignancies
A Phase I, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Doses of MEDI-575 in Patients With Advanced Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of MEDI-575 in Japanese patients with advanced solid tumors (dose escalation part) and hepatocellular carcinoma (expansion part).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEDI-575 | MEDI-575 will be administered weekly or every 3 weeks as IV infusion as part of a 21-day treatment cycle. One or two doses will be selected for expansion part |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2010-04-13
- Last updated
- 2013-02-06
Locations
5 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01102400. Inclusion in this directory is not an endorsement.